Citigroup Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and raises the price target from $30 to $34.
August 16, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Syndax Pharmaceuticals and raises the price target from $30 to $34.
The raised price target and maintained Buy rating from a reputable analyst at Citigroup is likely to positively impact investor sentiment and drive short-term price appreciation for Syndax Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100